MDMA oral transmucosal film compositions, methods of making, and methods of use thereof

Film compositions of (R)-MDMA with a polymeric carrier matrix offer a convenient and effective treatment for neurological disorders, addressing the need for controlled administration and minimizing side effects through mucoadhesive transmucosal delivery.

WO2026241750A1PCT designated stage Publication Date: 2026-11-19ATAI THERAPEUTICS INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028643
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-18
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a need for readily administrable medications of MDMA to treat neurological diseases and conditions, while maximizing efficacy and controlling drug side effects, and providing convenient routes of administration.

Method used

Film compositions comprising about 0.5% to about 70% by weight of (R)-3,4-methylenedioxymethamphetamine ((R)-MDMA) or a pharmaceutically acceptable salt thereof, and about 15% to about 80% by weight of a polymeric carrier matrix, which can be administered through a mucoadhesive product with a backing layer for transmucosal delivery.

Benefits of technology

The film compositions provide effective treatment for neurological disorders with controlled drug side effects and convenient administration, utilizing a mucoadhesive product for transmucosal delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028643_19112026_PF_FP_ABST
    Figure US2026028643_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are film compositions comprising MDMA or a pharmaceutically acceptable salt thereof and a polymeric carrier matrix.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: ATAI-114 / 01WO 338067-2911MDMA ORAL TRANSMUCOSAL FILM COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Application 63 / 807,296, filed May 16, 2025, the contents of which are hereby incorporated in its entirety.FIELD OF THE INVENTION

[0002] The present disclosure relates to compositions comprising (R)-MDMA, including films comprising (R)-MDMA or pharmaceutically acceptable salts thereof, and methods of making and using the same.BACKGROUND

[0003] 3,4-Methylenedioxymethamphetamine (MDMA) is a substituted amphetamine class, and its free base form is a colorless oil, insoluble in water. On the pharmacological level, MDMA is distinct from both LSD-type hallucinogens and amphetamines. MDMA itself is an amphetamine derivative that possesses complex pharmacology and is believed to act by increasing the release of monoamines like serotonin, norepinephrine and dopamine in the brain, as well as stimulating neurohormonal activity. These effects are thought to result in the anxiolytic, prosocial and empathic responses seen with MDMA administration in humans. As a result, MDMA is often classified as an entactogen rather than a typical psychedelic.

[0004] The prosocial effects of MDMA could play an important role in its therapeutic potential by increasing openness and facilitating a therapeutic alliance between patients and therapists. One of the most reliable behavioral features of MDMA is that it reduces aggression across species, along with reduced anxiety, lowered defensiveness, and a feeling of “closeness” with other persons. It is hypothesized that the effects of MDMA allow a person to voluntarily navigate difficult emotions when recalling traumatic memories due to a reduction in activity in the amygdala, a region of the brain activated during fear responses. This reduction in fear allows for a decreased defensiveness about revisiting painful experiences, making room for new perspectives and different responses towards deep-rooted traumatic memories.

[0005] A significant need exists for readily administrable medications of MDMA to treat neurological diseases and conditions. In particular, a need exists to maximize efficacy while controlling drug side effects while also providing for convenient routes of administration.1336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911SUMMARY

[0006] In embodiments, the present disclosure provides film compositions comprising: about 0.5 % to about 70 % by weight of (R)-3,4-methylenedioxymethamphetamine ((R)-MDMA) or a pharmaceutically acceptable salt thereof; and about 15% to about 80% by weight of a polymeric carrier matrix, wherein the (R)-MDMA or a pharmaceutically acceptable salt thereof incorporated within a polymeric carrier matrix.

[0007] In embodiments, the present disclosure provides a mucoadhesive product comprising a backing layer and a film composition as described herein.

[0008] In embodiments, the present disclosure provides a method of treating a neurological disorder, comprising administering a therapeutically effective amount of the film compositions of the present disclosure or the mucoadhesive product described herein.

[0009] In embodiments, the present disclosure provides methods of making the film compositions described herein, comprising: combining (R)-MDMA, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient in an aqueous solvent mixture; and removing the aqueous solvent mixture to provide a polymeric matrix comprising (R)-MDMA or a pharmaceutically acceptable salt thereof.BRIEF DESCRIPTON OF THE DRAWINGS

[0010] FIG. 1 depicts a schematic of a Franz diffusion cell system configured to simulate buccal transmucosal delivery conditions.DETAILED DESCRIPTIONDefinitions

[0011] Throughout this disclosure, various patents, patent applications and publications (including non-patent publications) are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference for all purposes in order to more fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications cited and this disclosure.

[0012] For convenience, certain terms employed in the specification, examples and claims are collected here. Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs.2336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0013] The term “about” when immediately preceding a numerical value means a range (e.g., plus or minus 10% of that value). For example, “about 50” can mean 45 to 55, “about 25,000” can mean 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation. For example, in a list of numerical values such as “about 49, about 50, about 55, ... ”, “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 52.5.

[0014] The terms "administer," "administering" or "administration" as used herein refer to administering a compound or pharmaceutically acceptable salt of the compound or a composition or formulation comprising a compound or pharmaceutically acceptable salt of the compound to a patient.

[0015] The terms “effective amount” and “therapeutically effective amount” are used interchangeably in this disclosure and refer to an amount of a compound, or a pharmaceutically acceptable salt thereof, that, when administered to a patient, is capable of performing the intended result.

[0016] The phrase “pharmaceutically acceptable” as used herein refers to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0017] The term “salts” as used herein embraces pharmaceutically acceptable salts commonly used to form alkali metal salts of free acids and to form addition salts of free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts can be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Appropriate organic acids can be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, and heterocyclyl containing carboxylic acids and sulfonic acids, for example formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, 3 -hydroxybutyric, galactaric and galacturonic acid.3336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0018] The term “treating” as used herein with regard to a patient, refers to improving at least one symptom of the patient’s disorder. Treating can be improving or at least partially ameliorating a disorder. For example, a patient’s opioid use disorder is treated when the method reduces at least one symptom of a neurological disorder in the patient.MDMA

[0019] The film compositions of the present disclosure contain MDMA or pharmaceutically acceptable salt thereof. The MDMA in the film compositions (or simply, films) of the present disclosure may be present in varying ratios of (R)-MDMA (or pharmaceutically acceptable salt thereof) or (S)-MDMA (or pharmaceutically acceptable salt thereof).

[0020] In embodiments, the film compositions comprise non-racemic mixtures of (R)-MDMA and (S)-MDMA.

[0021] In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is greater than 1. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is greater than 2, 3, 4 or 5. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is greater than 5.

[0022] In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is from 51 :49 to 99: 1. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is selected from the group consisting of 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 59:41, 60:40, 61:39, 62:38, 63:37, 64:36 , 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29, 72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, 80:20, 81:19, 82:18, 83:17, 84:16, 85:15, 86:14, 87:13, 88:12, 89:11, 90:10, 91:9, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 and 99:1.

[0023] In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is from 90: 10 to 99: 1. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is selected from the group consisting of 90: 10, 91:9, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 and 99:1. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is greater than 90:10. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is greater than 95:5, 96:4, 97:3, 98:2 or 99: 1. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is greater than 95:5. In embodiments, the weight ratio of (R)-MDMA to (S)-MDMA in the film compositions is less than 1.4336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0024] In embodiments, the film compositions comprise (R)-MDMA and are substantially free of (S)-MDMA, metabolite thereof (e.g., S-MDA), or a pharmaceutically acceptable salt thereof.

[0025] In embodiments, the film compositions comprise (R)-MDMA and less than 10%, less than 5%, less than 1%, less than 0.01%, less than 0.001%, less than 0.0001%, or less than 0.00001% (by weight) of (S)-MDMA, metabolite thereof (e.g., S-MDA), or a pharmaceutically acceptable salt thereof.

[0026] In embodiments, the film compositions comprise no or substantially no (S)-MDMA, a metabolite thereof (e.g., S-MDA), or a pharmaceutically acceptable salt thereof.

[0027] In embodiments, the enantiomeric purity of the (R)-MDMA in the film compositions is > 90%, > 95%, > 96%, > 97%, > 98%, > 99%, > 99.5%, > 99.9%, or > 99.99%. In embodiments, enantiomeric purity of the (R)-MDMA in the film compositions is > 98%. In embodiments, enantiomeric purity of the (R)-MDMA in the film compositions is 100%.

[0028] In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is greater than 1. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is greater than 2, 3, 4 or 5. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is greater than 5.

[0029] In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is from 51 :49 to 99: 1. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is selected from the group consisting of 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 59:41, 60:40, 61:39, 62:38, 63:37, 64:36 , 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29, 72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, 80:20, 81:19, 82:18, 83:17, 84:16, 85:15, 86:14, 87:13, 88:12, 89:11, 90:10, 91:9, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 and 99:1.

[0030] In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is from 90: 10 to 99: 1. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is selected from the group consisting of 90: 10, 91:9, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 and 99:1. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is greater than 90: 10. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is greater than 95:5, 96:4, 97:3, 98:2 or 99: 1. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is greater than 95:5. In embodiments, the weight ratio of (S)-MDMA to (R)-MDMA in the film compositions is less than 1.5336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0031] In embodiments, the film compositions comprise (S)-MDMA and are substantially free of (R)-MDMA, metabolite thereof (e.g., R-MDA), or a pharmaceutically acceptable salt thereof.

[0032] In embodiments, the film compositions comprise (S)-MDMA and less than 10%, less than 5%, less than 1%, less than 0.01%, less than 0.001%, less than 0.0001%, or less than 0.00001% (by weight) of (R)-MDMA, metabolite thereof (e.g., R-MDA), or a pharmaceutically acceptable salt thereof.

[0033] In embodiments, the film compositions comprise no or substantially no (R)-MDMA, metabolite thereof (e.g., R-MDA), or a pharmaceutically acceptable salt thereof.

[0034] In embodiments, the enantiomeric purity of the (S)-MDMA in the film compositions is > 90%, > 95%, > 96%, > 97%, > 98%, > 99%, > 99.5%, > 99.9%, or > 99.99%. In embodiments, enantiomeric purity of the (S)-MDMA in the film compositions is > 98%. In embodiments, enantiomeric purity of the (S)-MDMA in the film compositions is 100%.

[0035] In embodiments, the pharmaceutically acceptable salt of MDMA is an MDMA hydrochloride salt. For example, suitable salts of MDMA are described in U.S. Patent Application no. 18 / 116,195, which is incorporated by reference herein in its entirety.

[0036] In embodiments, the (R)-MDMA is a hydrochloride salt.

[0037] In embodiments, the (S)-MDMA is a hydrochloride salt.

[0038] In embodiments, the MDMA or a pharmaceutically acceptable salt thereof is crystalline.

[0039] In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof is crystalline.

[0040] In embodiments, the (S)-MDMA or a pharmaceutically acceptable salt thereof is crystalline.

[0041] In embodiments, the MDMA or a pharmaceutically acceptable salt thereof is amorphous. In embodiments, the MDMA or a pharmaceutically acceptable salt thereof is amorphous, and the film composition contains no more than 25 mol%, no more than 20 mol%, no more than 15 mol%, no more than 10 mol%, no more than 5 mol%, or no more than 2 mol%, of a crystalline MDMA. Crystal content may be determined using powder x-ray diffraction.

[0042] In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof is amorphous.

[0043] In embodiments, the (S)-MDMA or a pharmaceutically acceptable salt thereof is amorphous.6336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0044] In embodiments, the MDMA or a pharmaceutically acceptable salt thereof is characterized by a powder x-ray diffractogram free of any discernable peaks.

[0045] In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof is characterized by a powder x-ray diffractogram free of any discernable peaks.

[0046] In embodiments, the (S)-MDMA or a pharmaceutically acceptable salt thereof is characterized by a powder x-ray diffractogram free of any discernable peaks.

[0047] In embodiments, the MDMA or a pharmaceutically acceptable salt thereof is characterized by a differential scanning calorimetry (DSC) spectrum lacking a sharp melting endotherm of crystalline MDMA or a pharmaceutically acceptable salt thereof and / or lacking an indication of phase change.

[0048] In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof is characterized by a differential scanning calorimetry (DSC) spectrum lacking a sharp melting endotherm of crystalline (R)-MDMA or a pharmaceutically acceptable salt thereof and / or lacking an indication of phase change.

[0049] In embodiments, the (S)-MDMA or a pharmaceutically acceptable salt thereof is characterized by a differential scanning calorimetry (DSC) spectrum lacking a sharp melting endotherm of crystalline (S)-MDMA or a pharmaceutically acceptable salt thereof and / or lacking an indication of phase change.

[0050] The MDMA of the present disclosure may be prepared using methods that are known to those skilled in the art. For example, stereochemically pure (R)-MDMA (and stereochemically pure (S)-MDMA) may be synthesized and the purified stereoisomers combined in the ratios described herein. Racemic MDMA may also be resolved using chiral salt purification methods to provide stereochemically pure (R)-MDMA and (S)-MDMA. Similar methods may be used to provide the presently disclosed mixtures of (R)-MDMA and (S)-MDMA metabolites, such as MDA.Film Compositions

[0051] The following embodiments describe film compositions comprising (R)-MDMA, however, the present disclosure also contemplates embodiments where the MDMA is any form (e.g., (R)-MDMA or (S)-MDMA) and at various ratios of (R)-MDMA or (S)-MDMA as described herein.

[0052] In embodiments, the present disclosure provides film compositions comprising:

[0053] about 0.5% to about 70% by weight of (R)-MDMA or a pharmaceutically acceptable salt thereof; and7336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0054] about 15% to about 80% by weight of a polymeric carrier matrix, wherein the (R)-MDMA or a pharmaceutically acceptable salt thereof incorporated within a polymeric carrier matrix.

[0055] In embodiments, the film compositions comprise about 10% to about 60% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof, e.g., about 10%, about 20%, about 30%, about 40%, about 50%, or about 60%, including all values and ranges therebetween, by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof. In embodiments, the film compositions comprise about 15% to about 60%, or about 20% to about 60%, or about 30% to about 60%, or about 40% to about 60%, or about 50% to about 60%, or about 10% to about 50%, or about 10% to about 40%, or about 10% to about 30%, or about 10% to about 20%, or about 20% to about 50%, or about 30% to about 40% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof.

[0056] In embodiments, the film compositions comprise about 1% to about 40% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof, e.g., about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40%, including all values and ranges therebetween, by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof. In embodiments, the film compositions comprise about 2% to about 40%, or about 5% to about 40%, or about 1% to about 30%, or about 1% to about 20%, or about 1% to about 10%, or about 2% to about 20%, or about 5% to about 20%, or about 10% to about 20% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof.

[0057] In embodiments, the film compositions comprise about 40% to about 70% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof, e.g., about 40%, about 50%, about 60%, or about 70%, including all values and ranges therebetween, by weight the (R)-MDMA or a pharmaceutically acceptable salt thereof. In embodiments, the film compositions comprise about 50% to about 70%, or about 60% to about 70% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof.

[0058] In embodiments, the film compositions comprise about 20% to about 45% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof, e.g., from 20% to 40% by weight, 25% to 40% by weight, 30% to 40% by weight, 35% to 40% by weight, 30% to 45% by weight, 35% to 45% by weight, or 40% to 45% by weight.Polymer Carrier matrix

[0059] In embodiments, film compositions of the present disclosure comprise a polymer carrier matrix.8336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0060] In embodiments, the polymeric carrier matrix is a mucoadhesive polymer. In embodiments, the polymeric carrier matrix is suitable for transmucosal application. In embodiments, the transmucosal application is buccal, sublingual, gingival, on the tongue, nasal, vaginal, or a rectal application.

[0061] In embodiments, the polymeric carrier matrix comprises a cellulose derivative, a polyacrylic acid, a polyacrylate, a polyethylene oxide, polyvinyl pyrrolidone, poly(vinyl pyrrolidone-co-vinyl acetate), hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, a copolymer of l-vinyl-2-pyrrolidone and vinyl acetate, propylene glycol alginate ester, tragacanth, alginate, a gum, a soluble starch, gelatin, lectin, pectin, or chitosan, or a mixture thereof. In embodiments, the polymeric carrier matrix comprises carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), and a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate. In embodiments, the HPC of the polymeric carrier matrix comprises HPC-L, HPC-GXF, and HPC-SSL.

[0062] Physical characteristics of certain hydroxypropylcellulose polymers are described in the table below:Property HPC-SSL HPC-LF HPC-GXF* HPC-MFNippon Ashland Supplier-specific Ashland Typical supplier referenceSoda (Klucel LF) (GF-like) (Klucel MF)Brookfield Viscosity (mPa s, 4,000-6,5002-3 (2%) -75-150 (5%) -150-400 (2%)water, 25 °C) (2%)Relative molecular weight Very low Very high Low 95K Medium 370K(Daltons) 40k 850K

[0063] In embodiments, the film compositions comprise the polymeric carrier matrix in an amount of about 30% to about 70%, e.g., about 30%, about 40%, about 50%, about 60%, or about 70%, including all values and ranges therebetween, by weight. In embodiments, the film compositions comprise the polymeric carrier matrix in about 40% to about 70%, or about 50% to about 70%, or about 60% to about 70%, or about 30% to about 60%, or about 30% to about 50%, or about 30% to about 40%.9336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0064] In embodiments, the film compositions comprise about 40% to about 60% by weight of the polymeric carrier matrix. In embodiments, the film compositions comprise about 40% to about 50% by weight of the polymeric carrier matrix. In embodiments, the film compositions comprise about 50% to about 60% by weight of the polymeric carrier matrix. In embodiments, the film compositions comprise about 45% to about 55% by weight of the polymeric carrier matrix.

[0065] In embodiments, the polymeric carrier matrix comprises a mixture of at least two different polymers, which can differ by one or more of molecular structure, molecular weight, viscosity, or Tg. In embodiments, the polymeric carrier matrix comprises a first polymer having a Tgabove about 100°C, above about 105°C, above about 110°C, above about 115°C, above about 120°C, above about 125°C, above about 130°C, above about 140°C, above about 150°C, above about 175°C, or above about 200°C.

[0066] In embodiments, the polymeric carrier matrix comprises a first polymer having a Tgof about 100°C to about 200°C, about 100°C to about 150°C, about 100°C to about 125°C, about 100°C to about 115°C, about 125°C to about 150°C, about 125°C to about 175°C, or about 150°C to about 200°C.

[0067] In embodiments, the polymeric carrier matrix comprises a second polymer having a Tgbelow about 0°C, below about -5°C, below about -10°C, below about -15°C, below about -20°C, or below about -25°C.

[0068] In embodiments, the polymeric carrier matrix comprises a second polymer having a Tgof about -25°C to about 0°C, about -20°C to about 0°C, about -15°C to about 0°C, about -10°C to about 0°C, about -5°C to about 0°C, about -25°C to about -10°C, about -20°C to about -10°C, or about -15°C to about -5°C.

[0069] In embodiments, the polymeric carrier matrix can include one or more hydroxypropyl cellulose polymers. In embodiments, the polymeric carrier matrix can include at least two hydroxypropyl cellulose polymers, differing at least by average molecular weight. In embodiments, the polymeric carrier matrix can include hydroxypropyl cellulose SSL, hydroxypropyl cellulose LF, hydroxypropyl cellulose MF, hydroxypropyl cellulose GXF, or a combination thereof.

[0070] In embodiments, the polymeric carrier matrix can include a polyvinylpyrrolidone, for example one or more of copovidone, povidone K30, povidone K90, and combinations thereof.10336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0071] In embodiments, the MDMA is uniformly distributed throughout the carrier matrix. Distribution uniformity may be determined according to USP <905> “Uniformity of Dosage Unites Content Uniformity CU ”Other components

[0072] In embodiments, the film compositions of the present disclosure further comprise one or more of a permeation enhancer, buffering agent, saliva stimulating agent, stability enhancer, plasticizer, sweetening agent and / or a flavoring agent, coloring agent, hydrophilic adjuvant / additive or matrix solubilizing agent, antifoaming agent, or mixtures thereof.

[0073] In embodiments, the film compositions comprise a permeation enhancer. In embodiments, the film compositions comprise about 0.1% to about 30% by weight of the permeation enhancer, e.g., about 0.1%, about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%, including all values and ranges therebetween, by weight of the permeation enhancer.

[0074] In embodiments, the film compositions comprise about 0.1% to about 5% by weight of the permeation enhancer. In embodiments, the film compositions comprise about 0.1% to about 4% by weight of the permeation enhancer. In embodiments, the film compositions comprise the permeation enhancer in an amount of about 0.1% to about 1%, about 0.5% to about 1.5%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 2% to about 3%, about 2% to about 4%, or about 3% to about 4%.

[0075] In embodiments, the permeation enhancer comprises a bile salt, cetylpyridinium chloride (CPC), sodium lauryl sulfate (SLS), Tween 80, L-menthol, dimethyl sulfoxide (DMSO), oleic alcohol, oleic acid, oleyl oleate, levulinic acid, propylene glycol, dipropylene glycol, ethanol, d-alpha-tocopheryl polyethylene glycol succinate (vitamin E TPGS), or mixtures thereof.

[0076] In embodiments, the permeation enhancer comprises a bile salt, cetylpyridinium chloride (CPC), sodium lauryl sulfate (SLS), Tween 80, L-menthol, dimethyl sulfoxide (DMSO), oleic alcohol, oleic acid, oleyl oleate, levulinic acid, polyethylene glycol propylene glycol, dipropylene glycol, ethanol, d-alpha-tocopheryl polyethylene glycol succinate (vitamin E TPGS), or mixtures thereof.

[0077] In embodiments, the permeation enhancer comprises propylene glycol, glycerol, polyethylene glycol (“PEG”), or a combination thereof. In embodiments, the polyethylene glycol has a molecular weight (Mn) from about 120 Da to about 1,000 Da, from about 120 Da to about 500 Da, from about 120 Da to about 300 Da, from about 200 Da to about 400 Da, from about 200 Da to about 600, from about 250 Da to about 500 Da, from about 300 Da to 11336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911about 600 Da, from about 250 Da to about 1,000 Da, or from about 500 Da to about 1,000 Da.

[0078] In embodiments, the polyethylene glycol can be PEG 300, PEG 400, PEG 500, PEG 600, or a combination thereof.

[0079] In embodiments, the permeation enhancer comprises two of propylene glycol, glycerol, and polyethylene glycol, e.g., PEG 300. In embodiments, the permeation enhancer is propylene glycol and polyethylene glycol, e.g., PEG 300. In embodiments, the permeation enhancer is propylene glycol and glycerol. In embodiments, the permeation enhancer is glycerol and polyethylene glycol, e.g., PEG 300.

[0080] In embodiments, the film compositions comprise a buffering agent (which may also be designated a pH modulating agent). In embodiments, the film compositions comprise about 0.1% to about 10% by weight of the buffering agent, e.g., about 0.1%, about 2%, about 4%, about 6%, about 8%, or about 10%, including all values and ranges therebetween, by weight a buffering agent.

[0081] In embodiments, the buffering agent is present in the film composition in an amount from about 1% to about 10% by weight, from about 1% to about 5% by weight, from about 1% to about 3% by weight, from about 2% to about 10% by weight, from about 2% to about 5% by weight, from about 2% to about 4% by weight, from about 3% to about 6% by weight, from about 4% to about 8% by weight, from about 5% to about 10% by weight,

[0082] In embodiments, the buffering agent comprises citric acid, tartaric acid, fumaric acid, succinic acid, malic acid, sodium citrate, sodium tartrate, sodium succinate, sodium fumarate, sodium hydroxide, or mixtures thereof.

[0083] In embodiments, the buffering agent is present in an amount such that hydration of the film composition produces a film surface having a pH from about 6 to about 9, from about 7 to about 9, from about 8 to about 9, from about 7 to about 8, or from about 7.5 to about 8.5.

[0084] In embodiments, the buffering agent comprises sodium carbonate, sodium bicarbonate, or a combination thereof.

[0085] In embodiments, the film compositions comprise a saliva stimulating agent. In embodiments, the film compositions comprise about 0.1% to about 8% by weight of the saliva-stimulating agent, e.g., about 0.1%, about 2%, about 4%, about 6%, or about 8%, including all values and ranges therebetween, by weight of the saliva stimulating agent.

[0086] In embodiments, the saliva stimulating agent comprises citric acid, malic acid, lactic acid, ascorbic acid, tartaric acid, or mixtures thereof.12336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0087] In embodiments, the film compositions comprise a stability enhancer, wherein the stability enhancer comprises an antioxidant and / or a chelator. In embodiments, the film compositions comprise about 0.1% to about 5% by weight of the stability enhancer, e.g., about 0.1%, about 1%, about 2%, about 3%, about 4%, or about 5%, including all values and ranges therebetween, by weight of the stability enhancer.

[0088] In embodiments, the stability enhancer comprises a-tocopherol, tocopherol acetate, L-glutathione, L-cysteine, ascorbic acid, ascorbyl palmitate, propyl gallate, butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), tocopherol-based formulations (e.g., Tocobiol®), or ethylenediaminetetraacetic acid (EDTA), or mixtures thereof.

[0089] In embodiments, the film compositions comprise a sweetening agent and / or a flavoring agent. In embodiments, the sweetening agent comprises sucrose, dextrose, fructose, glucose, maltose, maltitol, saccharin, sucralose, neotame, cyclamate, aspartame, acesulfame-K, advantame, or mixtures thereof. In embodiments, the flavoring agent comprises peppermint oil, cinnamon oil, vanilla extract, menthol, L-menthol, arome type suppresseur amertume, lemon oil, natural lime flavor, or mixtures thereof.

[0090] In embodiments, the film compositions comprise a coloring agent including D&C red, D&C yellow, D&C blue, D&C green, FD&C red, yellow, green, blue, iron oxide red, iron oxide yellow, titanium dioxide or mixtures thereof.

[0091] In embodiments, the film compositions comprise a coloring agent including D&C red, D&C yellow, D&C blue, D&C green, FD&C red, yellow, green, blue, iron oxide red, iron oxide yellow, zinc oxide, titanium dioxide or mixtures thereof.

[0092] In embodiments, the coloring agent is present in the film composition in an amount from about 0.1% to about 5% by weight, from about 0.1% to about 2.5% by weight, from about 0.1% to about 1% by weight, from about 0.5% to about 2.5% by weight, from about 0.5% to about 1.5% by weight, from about 1% to about 5% by weight, from about 1% to about 2% by weight, from about 1% to about 3% by weight, from about 2% to about 4% by weight, or from about 3% to about 5% by weight.

[0093] In embodiments, the coloring agent is titanium dioxide, zinc oxide, or a combination thereof, in an amount from about 0.1% to about 5% by weight, from about 0.1% to about 2.5% by weight, from about 0.1% to about 1% by weight, from about 0.5% to about 2.5% by weight, from about 0.5% to about 1.5% by weight, from about 1% to about 5% by weight, from about 1% to about 2% by weight, from about 1% to about 3% by weight, from about 2% to about 4% by weight, or from about 3% to about 5% by weight. In embodiments, the coloring agent is titanium dioxide.13336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0094] In embodiments, the film compositions comprise a hydrophilic adjuvant / additive or matrix solubilizing agent wherein hydrophilic adjuvant and / or additive is cellulose derivative, starch derivative, cross linked povidone, cross linked cellulose, cross linked starch or alginate, sucrose, maltose, sugar alcohol or mixtures thereof.

[0095] In embodiments, the film compositions comprise an antifoaming agent including silicones, simethicone, stearyl alcohols, mineral oil, or mixtures thereof.

[0096] In embodiments, the film composition comprises propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, and hydroxypropyl cellulose MF. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and polyethylene glycol 300 are present in an amount that does not exceed 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

[0097] In embodiments, the film composition comprises propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, and hydroxypropyl cellulose SSL. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

[0098] In embodiments, the film composition comprises propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, and copovidone. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and copovidone in an amount of about 2% to about 10% by weight.

[0099] In embodiments, the film composition comprises propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, copovidone, and hydroxypropyl cellulose MF. In 14336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, copovidone in an amount of about 2% to about 10% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

[0100] In embodiments, the film composition comprises propylene glycol, glycerol, hydroxypropyl cellulose LF, and hydroxypropyl cellulose MF. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and glycerol are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, glycerol in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

[0101] In embodiments, the film composition comprises propylene glycol, glycerol, hydroxypropyl cellulose LF, and hydroxypropyl cellulose SSL. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and glycerol are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, glycerol in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

[0102] In embodiments, the film composition comprises propylene glycol, glycerol, hydroxypropyl cellulose LF, and copovidone. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and glycerol are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, glycerol in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and copovidone in an amount of about 2% to about 10% by weight.

[0103] In embodiments, the film composition comprises propylene glycol, glycerol, hydroxypropyl cellulose LF, copovidone, and hydroxypropyl cellulose MF. In embodiments,15336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the propylene glycol and glycerol are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises propylene glycol in an amount of about 0.1% to about 3% by weight, glycerol in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, copovidone in an amount of about 2% to about 10% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

[0104] In embodiments, the film composition comprises glycerol, polyethylene glycol 300, hydroxypropyl cellulose LF, and hydroxypropyl cellulose MF. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the glycerol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

[0105] In embodiments, the film composition comprises glycerol, polyethylene glycol 300, hydroxypropyl cellulose LF, and hydroxypropyl cellulose SSL. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the glycerol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

[0106] In embodiments, the film composition comprises glycerol, polyethylene glycol 300, hydroxypropyl cellulose LF, and copovidone. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the glycerol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and copovidone in an amount of about 2% to about 10% by weight.

[0107] In embodiments, the film composition comprises glycerol, polyethylene glycol 300, hydroxypropyl cellulose LF, copovidone, and hydroxypropyl cellulose MF. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the 16336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911glycerol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, copovidone in an amount of about 2% to about 10% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

[0108] In embodiments, the film composition comprises glycerol, propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, and hydroxypropyl cellulose MF. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the glycerol, propylene glycol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

[0109] In embodiments, the film composition comprises glycerol, propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, and hydroxypropyl cellulose SSL. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the glycerol, propylene glycol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

[0110] In embodiments, the film composition comprises glycerol, propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, and copovidone. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the glycerol, propylene glycol and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by17336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, and copovidone in an amount of about 2% to about 10% by weight.[OHl] In embodiments, the film composition comprises glycerol, propylene glycol, polyethylene glycol 300, hydroxypropyl cellulose LF, copovidone, and hydroxypropyl cellulose MF. In embodiments, the film composition further comprises hydroxypropyl cellulose GXF. In embodiments, the glycerol, propylene glycol, and polyethylene glycol 300 are present in an amount that does not exceed 5% or 4% by weight. In embodiments, the film composition comprises glycerol in an amount of about 0.1% to about 3% by weight, propylene glycol in an amount of about 0.1% to about 3% by weight, polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight, hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight, copovidone in an amount of about 2% to about 10% by weight, and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.Pharmacokinetics

[0112] In embodiments, the administration of the film compositions of the present disclosure to a subject in need thereof provides a therapeutically effective plasma concentration of (R)-MDMA in the subject. In embodiments, the administration of the film compositions of the present disclosure provides a maximum plasma concentration Cmax of (R)-MDMA from about 150 to about 3000 ng / mL, about 200 to about 3000 ng / mL, about 250 to about 3000 ng / mL, about 300 to about 3000 ng / mL, about 350 to about 3000 ng / mL, about 400 to about 3000 ng / mL, about 450 to about 3000 ng / mL, about 500 to about 3000 ng / mL, about 550 to about 3000 ng / mL, about 600 to about 3000 ng / mL, about 650 to about 3000 ng / mL, about 700 to about 3000 ng / mL, about 750 to about 3000 ng / mL, about 800 to about 3000 ng / mL, about 850 to about 3000 ng / mL, about 900 to about 3000 ng / mL, about 1050 to about 3000 ng / mL, about 1100 to about 3000 ng / mL, about 1150 to about 3000 ng / mL, about 1200 to about 3000 ng / mL, about 1250 to about 3000 ng / mL, about 1300 to about 3000 ng / mL, about 1350 to about 3000 ng / mL, about 1400 to about 3000 ng / mL, about 1450 to about 3000 ng / mL, about 1500 to about 3000 ng / mL, about 1550 to about 3000 ng / mL, about 1600 to about 3000 ng / mL, about 1650 to about 3000 ng / mL, about 1700 to about 3000 ng / mL, about 1750 to about 3000 ng / mL, about 1800 to about 3000 ng / mL, about 1850 to about 3000 ng / mL, about 1900 to about 3000 ng / mL, about 1950 to about 3000 ng / mL, about 2000 to about 3000 ng / mL, about 2050 to about 3000 ng / mL, about 2100 to about 3000 ng / mL, about 2150 to about 3000 ng / mL, about 2200 to about 3000 ng / mL, about 2250 to 18336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911about 3000 ng / mL, about 2300 to about 3000 ng / mL, about 2350 to about 3000 ng / mL, about 2400 to about 3000 ng / mL, about 2450 to about 3000 ng / mL, about 2500 to about 3000 ng / mL, about 2550 to about 3000 ng / mL, about 2600 to about 3000 ng / mL, about 2650 to about 3000 ng / mL, about 2700 to about 3000 ng / mL, about 2750 to about 3000 ng / mL, about 2800 to about 3000 ng / mL, about 2850 to about 3000 ng / mL, about 2900 to about 3000 ng / mL, or about 2950 to about 3000 ng / mL, including any values or ranges therebetween, following administration of the film composition.

[0113] In embodiments, the administration of the film composition provides a C max of(R)-MDMA of about 200 to about 3000 ng / mL, about 250 to about 3000 ng / mL, about 300 to about 3000 ng / mL, about 350 to about 3000 ng / mL, about 400 to about 3000 ng / mL, about 450 to about 3000 ng / mL, about 500 to about 3000 ng / mL, about 550 to about 3000 ng / mL, about 600 to about 3000 ng / mL, about 650 to about 3000 ng / mL, about 700 to about 3000 ng / mL, about 750 to about 3000 ng / mL, about 800 to about 3000 ng / mL, about 850 to about 3000 ng / mL, about 900 to about 3000 ng / mL, about 950 to about 3000 ng / mL, about 1000 to about 3000 ng / mL, about 1050 to about 3000 ng / mL, about 1100 to about 3000 ng / mL, about 1150 to about 3000 ng / mL, about 1200 to about 3000 ng / mL, about 1250 to about 3000 ng / mL, about 1300 to about 3000 ng / mL, about 1350 to about 14000 ng / mL, about 1400 to about 3000 ng / mL, about 1450 to about 3000 ng / mL, about 1500 to about 3000 ng / mL, about 1550 to about 3000 ng / mL, about 1600 to about 3000 ng / mL, about 1650 to about 3000 ng / mL, about 1700 to about 3000 ng / mL, about 1750 to about 3000 ng / mL, about 1800 to about 3000 ng / mL, about 1850 to about 3000 ng / mL, about 1900 to about 3000 ng / mL, about 1950 to about 3000 ng / mL, about 2000 to about 3000 ng / mL, about 2050 to about 3000 ng / mL, about 2100 to about 3000 ng / mL, about 2150 to about 14000 ng / mL, about 2200 to about 3000 ng / mL, about 2250 to about 3000 ng / mL, about 2300 to about 3000 ng / mL, about 2350 to about 3000 ng / mL, about 2400 to about 3000 ng / mL, about 2450 to about 3000 ng / mL, about 2500 to about 3000 ng / mL, about 2550 to about 3000 ng / mL, about 2600 to about 3000 ng / mL, about 2650 to about 3000 ng / mL, about 2700 to about 3000 ng / mL, about 2750 to about 14000 ng / mL, about 2800 to about 3000 ng / mL, about 2850 to about 3000 ng / mL, about 2900 to about 3000 ng / mL, or about 2950 to about 3000 ng / mL, including any values or ranges therebetween, following administration of the film composition. In embodiments, the administration of the film composition provides a Cmax of (R)-MDMA of about 225 ng / mL, about 250 ng / mL, about 275 ng / mL, about 300 ng / mL, about 325 ng / mL, about 350 ng / mL, about 375 ng / mL, about 400 ng / mL, about 425 ng / mL, about 450 ng / mL, about 475 ng / mL, about 500 ng / mL, about 525 ng / mL, about 550 ng / mL, about 575 ng / mL,19336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911about 600 ng / mL, about 625 ng / mL, about 650 ng / mL, about 675 ng / mL, about 700 ng / mL, about 725 ng / mL, about 750 ng / mL, about 775 ng / mL, about 800 ng / mL, about 825 ng / mL, about 850 ng / mL, about 875 ng / mL, about 900 ng / mL, about 925 ng / mL, about 950 ng / mL, about 975 ng / mL, about 1000 ng / mL, about 1025 ng / mL, about 1050 ng / mL, about 1075 ng / mL, about 1100 ng / mL, about 1125 ng / mL, about 1150 ng / mL, about 1175 ng / mL, about 1200 ng / mL, about 1225 ng / mL, about 1250 ng / mL, about 1275 ng / mL, about 1300 ng / mL, about 1325 ng / mL, about 1350 ng / mL, about 1375 ng / mL, about 1400 ng / mL, about 1425 ng / mL, about 1450 ng / mL, about 1475 ng / mL, about 1500 ng / mL, about 1525 ng / mL, about 1550 ng / mL, about 1575 ng / mL, about 1600 ng / mL, about 1625 ng / mL, about 1650 ng / mL, about 1675 ng / mL, about 1700 ng / mL, about 1725 ng / mL, about 1750 ng / mL, about 1775 ng / mL, about 1800 ng / mL, about 1825 ng / mL, about 1850 ng / mL, about 1875 ng / mL, about 1900 ng / mL, about 1925 ng / mL, about 1950 ng / mL, about 1975 ng / mL, about 2000 ng / mL, about 2025 ng / mL, about 2050 ng / mL, about 2075 ng / mL, about 2100 ng / mL, about 2125 ng / mL, about 2150 ng / mL, about 2175 ng / mL, about 2200 ng / mL, about 2225 ng / mL, about 2250 ng / mL, about 2275 ng / mL, about 2300 ng / mL, about 2325 ng / mL, about 2350 ng / mL, about 2375 ng / mL, about 2400 ng / mL, about 2425 ng / mL, about 2450 ng / mL, about 2475 ng / mL, about 2500 ng / mL, about 2525 ng / mL, about 2550 ng / mL, about 2575 ng / mL, about 2600 ng / mL, about 2625 ng / mL, about 2650 ng / mL, about 2675 ng / mL, about 2700 ng / mL, about 2825 ng / mL, about 2850 ng / mL, about 2875 ng / mL, to about 2900 ng / mL, about 2925 ng / mL, about 2950 ng / mL, about 2975 ng / mL, or about 3000 mg / mL, including any values or ranges therebetween, following administration of the film composition.

[0114] In embodiments, the administration of the film compositions of the present disclosure provide a plasma concentration ratio of (R)-MDMA to (S)-MDMA ranging from about 50.01:49.99 to about 100:0 (e.g., about 50.1:49.9, about 50.5:49.5, about 51:49, about 52:48, about 53:47, about 54:46, about 55:45, about 56:44, about 57:43, about 58:42, about 59:41, about 60:40, about 61:39, about 62:38, about 63:37, about 64:36 , about 65:35, about 66:34, about 67:33, about 68:32, about 69:31, about 70:30, about 71:29, about 72:28, about 73:27, about 74:26, about 75:25, about 76:24, about 77:23, about 78:22, about 79:21, about 80:20, about 81:19, about 82:18, about 83:17, about 84:16, about 85:15, about 86:14, about 87:13, about 88:12, about 89:11, about 90:10, about 91:9, about 92:8, about 93:7, about 94:6, about 95:5, about 96:4, about 97:3, about 98:2, about 99:1, about 99.5:0.5, about 99.9:0.1, or about 100:0, among other ratios within these enumerated ratios).

[0115] In embodiments, the administration of the film compositions of the present disclosure provide a Tmax of (R)-MDMA of about 1 hour to about 10 hours (such as about 2 hours to 20336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911about 8 hours, about 3 hours to about 8 hours, or about 3 hours to about 5 hours), for example, about 1 hour, 1.25 hours, about 1.5 hours, about 1.75 hours, about 2.0 hours, about 2.25 hours, about 2.5 hours, about 2.75 hours, about 3.0 hours, about 3.25 hours, about 3.5 hours, about 3.75 hours, about 4.0 hours, about 4.25 hours, about 4.5 hours, about 4.75 hours, about 5.0 hours, about 5.25 hours, about 5.5 hours, about 5.75 hours, about 6.0 hours, about 6.25 hours, about 6.5 hours, about 6.75 hours, about 7.0 hours, about 7.25 hours, about 7.5 hours, about 7.75 hours, about 8.0 hours, about 8.25 hours, about 8.5 hours, about 8.75 hours, about 9.0 hours, about 9.25 hours, about 9.5 hours, about 9.75 hours, or about 10 hours, including any values or ranges therebetween following administration of the film composition.

[0116] In embodiments, the administration of the film compositions of the present disclosure provide a T1 / 2 of (R)-MDMA of about 5 hour to about 20 hours, for example, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, or about 20 hours, including any values or ranges therebetween following administration of the film composition.

[0117] In embodiments, the administration of the film compositions of the present disclosure provide a Tmax of (R)-MDA of about 5 hours to about 30 hours (such as about 10 hours to about 24 hours), for example, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, or about 15 hours, about 16 hours, about 16.5 hours, about 17 hours, about 17.5 hours, about 18 hours, about 18.5 hours, about 19 hours, about 19.5 hours, about 20 hours, about 20.5 hours, about 21 hours, about 21.5 hours, about 22 hours, about 22.5 hours, about 23 hours, about 23.5 hours, about 24 hours, about 24.5 hours, or about 25 hours, about 26 hours, about 26.5 hours, about 27 hours, about 27.5 hours, about 28 hours, about 28.5 hours, about 29 hours, about 29.5 hours, or about 30 hours, including any values or ranges therebetween, following administration of the film composition.

[0118] In embodiments, the administration of the film composition provides a AUCo-t of (R)-MDMA of about 2000 ng h / mL to about 20,000 ng h / mL, for example, about 2000 ng h / mL, about 3000 ng h / mL, about 4000 ng h / mL, about 5000 ng h / mL, about 6000 ng h / mL, about 7000 ng h / mL, about 8000 ng h / mL, about 9000 ng h / mL, about 10,000 ng h / mL, about 11,000 ng h / mL, about 12,000 ng h / mL, about 13,000 ng h / mL, about 14,000 ng h / mL,21336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911about 15,000 ng h / mL, 16,000 ng h / mL, about 17,000 ng h / mL, about 18,000 ng h / mL, about 19, 000 ng h / mL, or about 20,000 ng h / mL, including any values or ranges therebetween, following administration of the film composition.

[0119] In embodiments, the administration of the film composition provides a AUCo-t of (R)-MDA of about 100 ng h / mL to about 800 ng h / mL, for example, about 100 ng h / mL, about 150 ng h / mL, about 200 ng h / mL, about 250 ng h / mL, about 300 ng h / mL, about 350 ng h / mL, about 400 ng h / mL, about 450 ng h / mL, about 500 ng h / mL, about 550 ng h / mL, about 600 ng h / mL, about 650 ng h / mL, about 700 ng h / mL, about 750 ng h / mL, about 800 ng h / mL, including any values or ranges therebetween, following administration of the film composition.

[0120] In embodiments, following administration of the film composition, R-MDA (metabolite of R-MDMA) remains in the plasma for days. This is due to the protracted ’A life of R-MDA where a prolonged T1 / 2 results in R-MDA remaining in the plasma for an extended period of time.Film Characteristics

[0121] In embodiments, the film composition is in the form of an oral transmucosal film.

[0122] In embodiments, the oral transmucosal film thickness is about 0.01 mm to about 2 mm, e.g., about 0.01 mm, about 0.02 mm, about 0.05 mm, about 0.2 mm, about 0.5 mm, about 1 mm, about 1.2 mm, about 1.5 mm, or about 2mm, including all values and ranges therebetween. In embodiments, the oral transmucosal film thickness is about 0.02 mm to about 2 mm, or about 0.02 mm to about 1.5 mm, or about 0.02 mm to about 1 mm, or about 0.05 mm to about 2 mm, or about 0.05 mm to about 1.5 mm, or about 0.05 mm to about 1 mm, or about 0.05 mm to about 0.6 mm, or about 0.05 mm to about 0.2 mm, or about 0.1 mm to about 1 mm, or about 0.2 mm to about 1 mm, or about 0.4 mm to about 1 mm.

[0123] In embodiments, the loss on drying (LOD) of the film is about 2-15 % w / w, e.g., about 2% w / w, about 3% w / w, about 5% w / w, about 10% w / w, or about 15% w / w, including all values and ranges therebetween as determined by thermogravimetric analysis (TGA) at a temperature from 90-100 °C for a period of 10 minutes. In embodiments, the film compositions exhibit a loss on drying (LOD) of about 1% to about 10%, about 2% to about 8%, about 2% to about 7%, about 2.5% to about 6%, about 3% to about 10%, about 3% to about 8%, about 3% to about 7%, or about 3% to about 6.5%, as determined by thermogravimetric analysis (TGA) at a temperature from 90-100 °C for a period of 10 minutes.22336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0124] In embodiments, the film comprises about 1-20 mg / cm2of (R)-MDMA or a pharmaceutically acceptable salt thereof, e.g., about 1 mg / cm2, about 5 mg / cm2, about 10 mg / cm2, or about 20 mg / cm2, including all values and ranges therebetween, of (R)-MDMA or pharmaceutically acceptable salt thereof.

[0125] In embodiments, a pharmaceutical strip of the film (e.g., a single buccal dosage that a patient may buccally apply) about 1 mg to about 150 mg of (R)-MDMA or pharmaceutically acceptable salt thereof, e.g., about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, or about 150 mg, including all values and ranges therebetween, of (R)-MDMA or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical strip of the film comprises about 30-50 mg, 50-80 mg, or 50-150 mg of (R)-MDMA or pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical strip of the film comprises about 50-80 mg per film (R)-MDMA or pharmaceutically acceptable salt thereof.Stability

[0126] In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof remains in an amorphous state following storage of the film composition at 25°C and 60% relative humidity for 6 months. In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof remains in an amorphous state following storage of the film composition at 40°C and 75% relative humidity for 6 months.

[0127] In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof remains in an amorphous state following storage of the film composition at 2°C to 8°C and 60% relative humidity for 6 months. In embodiments, the (R)-MDMA or a pharmaceutically acceptable salt thereof remains in an amorphous state following storage of the film composition at 2°C to 8°C and 75% relative humidity for 6 months.

[0128] In embodiments, the film compositions exhibit a folding endurance of at least 10 folds without breaking.

[0129] In embodiments, the film compositions exhibit a tensile strength of about 1 MPa to about 10 MPa, about 1 MPa to about 5 MPa, about 2 MPa to about 9 MPa, about 2 MPa to about 5 MPa, about 3 MPa to about 10 MPa, about 3 MPa to about 7 MPa, or about 5 MPa to about 10 MPa as measured by ASTM D638.

[0130] In embodiments, the film compositions exhibit an elongation at break of about 10% to about 50%, about 30% to about 70%, or about 50% to about 100%, as measured by ASTM D882.23336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0131] In embodiments, at least 10% of the MDMA, e.g., (R)-MDMA in the film composition permeates in vitro through a buccal membrane within 4 hours, determined using a buccal porcine membrane assay as described herein. In embodiments, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, of the MDMA, e.g., (R)-MDMA permeates in vitro through a buccal membrane within 4 hours, determined using a buccal porcine membrane assay as described herein.

[0132] In embodiments, wherein the (R)-MDMA is amorphous, the amorphous state is characterized by a powder x-ray diffractogram free of any discernable peaks, or characterized by a differential scanning calorimetry (DSC) spectrum for absence of sharp melting endotherm of crystalline MDMA or a pharmaceutically acceptable salt thereof and / or indication of phase change (e.g., glass transition temperature).Product

[0133] In embodiments, the present disclosure provides for a mucoadhesive product comprising a backing layer and the film composition as otherwise described herein.

[0134] In embodiments, the mucoadhesive product is in the form of a film.

[0135] In embodiments, the backing layer is adapted to reduce or prevent (R)-MDMA or a pharmaceutically acceptable salt thereof from being transported across the backing layer while the mucoadhesive product is being administered.

[0136] In embodiments, the backing layer comprises a backing polymeric carrier matrix and pigment. In embodiments, the backing polymeric carrier matrix comprises carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), and a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate. In embodiments, the pigment comprises titanium dioxide.

[0137] In embodiments, the backing layer comprises:60-75 wt % Nisso HPC-L10-20 wt % PEG3005-10 wt % CMC (ashland 7LF)3-8 wt % Plasdone S-6301-5 wt % Titanium dioxide (TiCh)0.5-3 wt % NaOH 50%

[0138] In embodiments, the backing layer comprises:24336663861Attorney Docket No.: ATAI-114 / 01WO 338067-291168.42 wt % Nisso HPC-L14.31 wt % PEG3007.80 wt % CMC (ashland 7LF)5.96 wt % Plasdone S-6302.08 wt % Titanium dioxide (TiCh)1.43 wt % NaOH 50%Methods of Treatment

[0139] The present disclosure provides methods used to treat a neurological disease, disorder, or condition, (inclusive of, e.g., a mental health disease, disorder, or condition). The methods comprise administering a film composition of the disclosure to a subject in need thereof.

[0140] As referred to herein, a “neurological disease disorder, or condition” refers to a disease, disorder, or condition that can comprise: a neuropsychiatric disorder, such as depression (including severe depression such as treatment-resistant depression (TRD), major depressive disorder (MDD) and persistent depressive disorder), alexithymia, catatonic depression, a depressive disorder due to a medical condition, postpartum depression, premenstrual dysphoric disorder, seasonal affective disorder, anxiety, anxiety disorder, social anxiety disorder (SAD), general anxiety disorder (GAD), avolition disorder, bipolar disorder (including bipolar I disorder and bipolar II disorder), post-traumatic stress disorder (PTSD), Cluster C personality disorders, rejection sensitivity dysphoria / disorder, body dysmorphic disorder, abnormalities of mood or emotion, including the above conditions, dysthymia, schizoaffective disorder, schizophrenia and other psychotic disorders, panic disorder, traumatic stress disorders, phobic disorders, and personality disorders with abnormal mood, such as borderline personality disorder, schizoid and schizotypal disorders, suicide ideation, rumination / unproductive repetitive thoughts negatively impacting one’s behavior, mood, and / or ability to focus, obsessive-compulsive disorder, addiction (including substance use disorders, such as addiction to nicotine, alcohol, cocaine, opioids, amphetamine, methamphetamine, heroin, morphine, phencyclidine, 3, 4-methylenedi oxy -methamphetamine, as well as other addictive substances), addictive behavior (including eating, gambling, sex, pornography, videogames, work, exercise, spiritual obsession, self-harm, travel and shopping addiction, etc.), eating disorders (including anorexia nervosa, bulimia nervosa and binge 25336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911eating disorder), and pain (including pain associated with migraine or headache or chronic pain).

[0141] In embodiments, the disclosure relates to the use of the film compositions for treating or alleviating one or more neurological diseases, disorders, or conditions. In embodiments, the neurological disease, disorder, or condition comprises a mental health disease, disorder, or condition. Such conditions include those identified herein, which are described and discussed in the Diagnostic and Statistical Manual of Mental Disorders (5thed.; DSM-5; American Psychiatric Association, 2013), the content of which is incorporated by reference in its entirety for any purpose.

[0142] In embodiments, the disclosure provides methods for the treatment of an anxiety disorder. In embodiments, the anxiety disorder is one or more of generalized anxiety disorder (GAD), phobia, social anxiety disorder (SAD), social phobia, specific phobia, panic disorder, panic attack, panic attack specifier, separation anxiety disorder, selective mutism, agoraphobia, situation anxiety or an anxiety disorder induced by a substance / medication or due to another medical condition.

[0143] In embodiments, the present disclosure provides methods of treating SAD by administering the film composition to a subject in need thereof.

[0144] In embodiments, the disclosure provides methods of treating post-traumatic stress disorder, an eating disorder, or obsessive-compulsive disorder by administering the film composition to a subject in need thereof.

[0145] In embodiments, the methods of treating comprise applying a film composition or mucoadhesive product described herein buccally, sublingually, gingivally, on the tongue, nasally, vaginally, or rectally. In embodiments, a film composition or mucoadhesive product described herein is applied buccally.Methods of Manufacturing

[0146] In embodiments, the present disclosure provides methods of making film compositions described herein, comprising:combining (R)-MDMA, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipient in an aqueous solvent mixture; andremoving the aqueous solvent mixture to provide a polymeric matrix comprising (R)-MDMA or a pharmaceutically acceptable salt thereof.26336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0147] In embodiments, the solvent comprises methanol and water. In embodiments, the solvent comprises methanol: water in a 50:50 weight or volume ratio, or comprises water alone.

[0148] In embodiments, method of making comprises the step of preparing a mixture of MDMA, e.g., (R)-MDMA in a solvent system along with one or more excipients, e.g., polymer, permeation enhancer, buffering agent, etc., casting the mixture onto a substrate and removing the solvent system to prepare a film. In embodiments, the solvent system comprises a low polarity solvent and a polar solvent. Exemplary low polarity solvents include ethyl acetate and methyl ethyl ketone. Exemplary polar solvents include alcohols like methanol, ethanol, or isopropanol. In embodiment the low polarity solvent in present in a greater solvent fraction than the polar solvent. In embodiments, the low polarity solvent is present in an amount of greater than 50% solvent fraction, greater than 60% solvent fraction, greater than 70% solvent fraction, greater than 80% solvent fraction, or greater than 90% solvent fraction. In embodiments, the low polarity solvent:polar solvent ratio is from 51 :49 to 90:10, from 60:40 to 90:10, from 70:30 to 90:10, from 80:20 to 90:10, from 60:40 to 80:20, from 70:30 to 80:20, or from 75:25 to 85:15.

[0149] In embodiments, the method comprises casting the polymeric matrix by removing the solvent to form a film. In embodiments, prior to casting the mixture is de-aerated, optionally with low-speed mixing.

[0150] In embodiments, the film composition is an oral transmucosal film.EXAMPLESExample 1: Oral film # 1

[0151] An oral film having the following composition was prepared:Ingredients Amount (g) % wet (w / w) % dry (w / w) Propylene glycol 0.082 0.18 0.86 Glycerol 0.156 0.34 1.64Ethyl acetate 29.355 63.56 —IPA 7.339 15.89 —TiCh 0.074 0.16 0.78Sodium Carbonate 0.263 0.57 2.77 Yellow # 10 0.014 0.03 0.15 Neotame 0.095 0.21 1.01L-Menthol 0.150 0.32 1.5827336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911Ingredients Amount (g) % wet (w / w) % dry (w / w) MDMA HC1 2.963 6.42 31.23 HPC SSL 0.602 1.30 6.34 Plasdone S630 0.506 1.10 5.33 HPC Klucel LF 4.583 9.92 48.30 Total wet 46.18 100.00 — Total dry 9.49 — — % solids 20.54 — — Film surface pH — — 7.94 Film target weight for 40— — 128.10mg MDMA HC1 (mg)Tensile strength TS at— — 6.39break (Mpa)Elongation % at break — — 42.54 Thickness microns — — 148LOD % — — 2.8Average Permeation after— — 22%4 Hours (% of dose)

[0152] A solvent system of controlled polarity was prepared comprising either isopropanol (IPA):ethyl acetate (EA) 20:80 (w / w) or isopropanol (IPA):methyl ethyl ketone (MEK) 20:80 (w / w).

[0153] At least one permeation enhancer was incorporated into the solvent system, including but not limited to propylene glycol, glycerol, and polyethylene glycol. These components act synergistically to improve polymer chain mobility, reduce glass transition temperature, and enhance film flexibility, enabling mechanically balanced films at high dispersed API loadings.

[0154] A buffering agent was added to the said solvent system, including but not limited to: sodium carbonate, sodium bicarbonate, other pharmaceutically acceptable basifying agents or buffer systems.

[0155] When the film is hydrated, the buffering agent establishes a microenvironmental pH of approximately 8.0 ± 0.5 near the drug pKa.

[0156] Opacifier was added to the said solvent system, including but not limited to titanium dioxide T1O2 or zinc oxide. T1O2 masks visible dispersed drug particles and improves visual28336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911uniformity, acts as inert, insoluble micro-fillers that physically separate dispersed API particles, reducing direct particle-particle contact.

[0157] Optional excipients can also be added, including: colorants, sweeteners, flavoring agents, bitter masking agents.

[0158] MDMA HC1 salt of approximately 30-40% by dry weigh was added to the previously added excipients.

[0159] All formulation components were dispersed under high-shear homogenization to achieve a uniform and stable distribution of the active ingredient and excipients within the solvent phase prior to polymer matrix formation.

[0160] Film-forming polymers were added gradually under continuous mixing. The polymer solution is mixed until fully uniform and homogeneous prior to casting, ensuring consistent matrix formation and performance.

[0161] First polymer group - lower glass transition temperature (Tg) polymers including but not limited to hydroxypropylcellulose - super low viscosity (HPC SSL), hydroxypropylcellulose low viscosity (L) grade (HPC LF.)

[0162] Second polymer group - higher Tgstructural polymers including but not limited to: Copovidone, Povidone K30 and Povidone K90.

[0163] The resulting mixture was de-aerated using low mixing speed. De-aeration prevents bubble formation, improves film uniformity, and enhances mechanical strength.

[0164] The de-aerated mixture was cast onto a suitable substrate using a film applicator or casting equipment at controlled thickness. The cast film was dried under controlled temperature and airflow conditions to achieve a loss on drying (LOD) of approximately 2.5% to 6%.

[0165] Controlled drying achieves polymer chain consolidation, immobilization of API particles, formation of continuous polymer network, preservation of elasticity and tensile strength. The controlled LOD ensures optimal polymer mobility and stress transfer.

[0166] The dried film was removed from the substrate and cut into individual strips of predetermined dimensions.Example 2: Oral film # 2

[0167] An oral film having the following composition was prepared:Ingredients Amount (g) % wet (w / w) % dry (w / w) Glycerol 0.084 0.43 2.07Peg 300 0.066 0.34 1.6329336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911Ingredients Amount (g) % wet (w / w) % dry (w / w) Ethyl acetate 12.278 63.30 — IPA 3.069 15.82 — TiCh 0.037 0.19 0.91 Sodium Carbonate 0.138 0.71 3.41 Yellow # 10 0.007 0.04 0.18 Neotame 0.030 0.15 0.73 L-Menthol 0.074 0.38 1.83 MDMA HC1 1.484 7.65 36.64 HPC MF 0.300 1.55 7.41 HPC Klucel LF 1.830 9.43 45.19 Total wet 19.397 100.00 — Total dry 4.050 — 100.00 % solids 20.878 — — Film surface pH — — 8.11 Film target weight for 40— — 109.18 mg MDMA HC1 (mg)Tensile strength YS at— — 7.93 break (Mpa)Elongation % at break — — 30.72 Thickness microns — — 137 LOD % — — 2.00 Average Permeation after 4— — 24.8% Hours (% of dose)30336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0168] In Example #2, The film was prepared according to example #1. The resulting film was uniform, mechanically coherent, and passed the folding endurance test, exhibiting a tensile strength of approximately 8 MPa and elongation at break of approximately 31%.Example 3: Oral film # 3

[0169] An oral film having the following composition was prepared:Ingredients Amount (g) % wet (w / w) % dry (w / w) Propylene glycol 0.044 0.23 1.08 Glycerol 0.084 0.43 2.06Peg 300 0.044 0.23 1.08Ethyl acetate 12.278 63.22 —IPA 3.069 15.80 —TiCh 0.037 0.19 0.91Sodium Carbonate 0.140 0.72 3.44 Yellow # 10 0.007 0.04 0.18 Neotame 0.030 0.15 0.73L-Menthol 0.074 0.38 1.82 MDMA HC1 1.484 7.64 36.42 HPC MF 0.300 1.54 7.36HPC Klucel LF 1.830 9.42 44.92 Total wet 19.421 100.00 — Total dry 4.074 — 100.00% solids 20.976 — — Film surface pH — — 8.05 Film target weight for 40— — 109.83mg MDMA HC1 (mg)Tensile strength TS at— — 5.79break (Mpa)31336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911Ingredients Amount (g) % wet (w / w) % dry (w / w) Elongation % at break — — 32.42 Thickness microns — — 158 LOD % — — 1.3 Average Permeation after— — 20.6%4 Hours (% of dose)

[0170] In example #3, the film was prepared according to example #1. The resulting film was uniform, fold-resistant, and mechanically coherent.Example 4: Oral film # 4

[0171] An oral film having the following composition was prepared:Ingredients Amount (g) % wet (w / w) % dry (w / w) Propylene glycol 0.039 0.20 0.97 Glycerol 0.077 0.40 1.92 Ethyl acetate 12.278 63.44 —IPA 3.069 15.86 —TiCh 0.037 0.19 0.92 Sodium Carbonate 0.138 0.71 3.44 Yellow # 10 0.007 0.04 0.18 Neotame 0.030 0.15 0.74L-Menthol 0.074 0.38 1.85 MDMA HC1 1.480 7.65 36.94 HPC GXF 0.200 1.03 4.99 HPC MF 0.225 1.16 5.62 HPC Klucel LF 1.700 8.78 42.43 Total wet 19.354 100.00 — Total dry 4.007 — 100.0032336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911Ingredients Amount (g) % wet (w / w) % dry (w / w) % solids 20.703 — — Film surface pH — — 8 Film target weight for 40— — 18.29 mg MDMA HC1 (mg)Tensile strength TS at— — 6.52 break (Mpa)Elongation % at break — — 36.11 LOD % — — 2 Thickness microns — — 160 Average Permeation after 4— — 29.5% Hours (% of dose)Comparative Example 5 and 6Example #5Ingredients Amount (g) % wet (w / w) % dry (w / w)IPA 8.20 40.46 - MEK 8.20 40.46 - MDMA HC1 1.61 7.92 41.52 Sucralose 0.05 0.27 1.40 Plasdone s630 0.14 0.67 3.52 HPC Klucel LF 1.62 7.99 41.91 HPC Klucel GXF 0.24 1.19 6.26 Triacetin 0.21 1.03 5.40 Total wet 20.27 100.00 — Total dry 3.87 — 100.00 % solids 19.08 — —33336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911Ingredients Amount (g) % wet (w / w) % dry (w / w)Film target weightfor 40 mg MDMA — — 96.34HC1 (mg)Example #6Ingredients Amount (g) % wet (w / w) % dry (w / w)IPA 16.20 80.73 —MEK 0.00 0.00 —MDMA HC1 1.61 8.00 41.52Sucralose 0.05 0.27 1.40Plasdone s630 0.14 0.68 3.52HPC Klucel LF 1.62 8.07 41.91HPC Klucel GXF 0.24 1.21 6.26Glycerol 0.21 1.04 5.40Total wet 20.07 — —Total dry 3.87 100.00 100.00% solids 19.27 — —Film target weightfor 40 mg MDMA — — 96.34HC1 (mg)

[0172] Example #5 was prepared in accordance with Example #1, except that the solvent system comprised isopropanol and methyl ethyl ketone in an equal ratio (50:50 w / w). The polymer matrix included lower Tgpolymers (HPC LF and HPC GXF) in combination with a higher Tgstructural polymer (Plasdone S630). Triacetin was incorporated at approximately 5.4% w / w as the permeation enhancer, and sucralose was included as a sweetener. The formulation did not contain a buffering agent, flavoring agents, dye, or opacifier.34336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0173] Example #6 was prepared according to Example #5, except that the solvent system comprised 100% isopropanol and 5.4% w / w glycerol was used as the permeation enhancer.

[0174] In both Examples #5 and #6, the system failed to form a continuous film during drying and instead produced a cracked, brittle, non-cohesive sheet.Comparative Example 7Ingredients Amount (g) % wet (w / w) % dry (w / w) Ethyl acetate 12.211 64.97 - IPA 3.053 16.24 - Propylene glycol 0.036 0.19 1.02Sodium Carbonate 0.117 0.62 3.32MDMA HC1 1.500 7.98 42.48Neotame 0.035 0.19 0.99TiO2 0.050 0.27 1.42Plasdone k90 0.137 0.73 3.88HPC Klucel LF 1.656 8.81 46.90Total wet 18.795 100.00 —Total dry 3.531 — 100.00% solids 18.788 — —Film surface pH — — 4.66Film target weight 94.17for 40 mg MDMAHC1 (mg)Tensile strength YS — — 11.1at break (Mpa)Elongation % at — — 17.4breakThickness microns — — 11535336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911Ingredients Amount (g) % wet (w / w) % dry (w / w)Average Permeationafter 4 Hours (% of 8dose)

[0175] Example #7 was prepared according to example #1 using solvent system comprised IPA:EA 20:80 (w / w), propylene glycol approximately 1% w / w as permeation enhancer, sodium carbonate was added as a pH modulator, TiCh as opacifier and Neotame as sweetener. The formulation further comprised approximately 47% w / w HPC LF (lower Tgfilm forming polymer), 4% w / w Povidone K90 (higher Tgfilm forming polymer), and approximately 42.5% w / w API.

[0176] The blend formed a continuous film after drying. However, the film did not meet the defined functional performance criteria of the invention. Permeation was significantly reduced to approximately 8% after 4 hours, well below the defined threshold of >20%.Comparative Example 8Ingredients Amount (g) % wet (w / w) % dry (w / w)Ethyl acetate 11.101 63.93 - IPA 2.775 15.98 - Propylene glycol 0.144 0.83 4.13MDMA HC1 1.458 8.40 41.78Sucralose 0.027 0.15 0.77TiO2 0.067 0.39 1.92Povidone K90 0.137 0.79 3.92HPC Klucel LF 1.656 9.54 47.47Total wet 17.37 100.00 —Total dry 3.49 — 100.00% solids 20.09 — —36336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911Ingredients Amount (g) % wet (w / w) % dry (w / w)Film target weightfor 40 mg MDMA — — 95.73HC1 (mg)

[0177] Example #8 was prepared according to Example #7 without buffering gent, except the API was approximately 41.8%, propylene glycol was incorporated at approximately 4.1% w / w as permeation enhancer and sucralose as sweetener.

[0178] The coated composition failed to form a continuous self-supporting film during drying and instead produced a tacky, paste-like layer that adhered to the liner.Example 9: In Vitro Transmucosal Permeation Method

[0179] In vitro permeation studies were conducted using a Franz diffusion cell system configured to simulate buccal transmucosal delivery conditions. The receptor and donor media each comprised phosphate-buffered saline (PBS, 0.01 M, pH 6.8), and the system was maintained at 37°C throughout the experiment. A porcine buccal mucosa membrane was mounted between the donor chamber and the receiver chamber to provide a biologically relevant barrier for evaluation of transmucosal drug transport.

[0180] Porcine buccal tissue was obtained from freshly sacrificed pigs. The excised cheek tissue was preserved in Krebs buffer at pH 7.4 and stored frozen until use. Prior to the experiment, the buccal mucosa was prepared and mounted in the Franz cell apparatus with the epithelial side facing the donor compartment.

[0181] Test samples active-containing film specimens were placed in the donor chamber in direct contact with the mucosal membrane. The donor chamber contained 1 mL of PBS at pH 6.8 and exposed a membrane surface area of 1.76 cm2. Each sample provided an equivalent amount of 4.2 mg of API, expressed as free base. The receiver chamber contained 12 mL of PBS at pH 6.8 and was continuously agitated during the study.

[0182] Aliquots were withdrawn from the receiver chamber at predetermined time points of 0.5, 1.0, 1.5, 2.5, and 4.0 hours. At each pull point, a 0.5 mL sample was collected from the receiver chamber, diluted with PBS at pH 6.8, and analyzed for drug content. Following each sampling event, the removed volume was replaced with an equal volume of fresh PBS at pH 6.8 in order to maintain sink conditions and constant receiver volume.

[0183] Permeation results were expressed as the percentage of drug transferred to the receiver chamber over time.37336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911

[0184] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

[0185] While the invention has been described in connection with proposed specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.ADDITIONAL EMBODIMENTS1. A composition comprising:about 0.5 % to about 70 % by weight of (R)-3,4-methylenedioxymethamphetamine ((R)-MDMA) or a pharmaceutically acceptable salt thereof; andabout 15% to about 80% by weight of a polymeric carrier matrix, wherein the (R)-MDMA or a pharmaceutically acceptable salt thereof incorporated within a polymeric carrier matrix.2. The composition of embodiment 1, wherein the composition comprises a weight ratio of (R)-MDMA to (S)-MDMA ranging from about 50.1:49.9 to about 100:0.3. The composition of embodiment 1, wherein the composition comprises (R)-MDMA in an enantiomerically enriched form of > 90%, > 95%, > 96%, > 97%, > 98%, > 99%, > 99.5%, > 99.9%, or > 99.99%, or 100% relative to total MDMA.4. The composition of embodiment 1, wherein the composition comprises (R)-MDMA in an enantiomeric excess to (S)-MDMA from about 95% to about 100%.5. The composition of embodiment 1, wherein the composition comprises (R)-MDMA in an enantiomeric excess to (S)-MDMA from about 98% to about 100%.6. The composition of any one of embodiments 1-6, wherein (R)-MDMA or pharmaceutically acceptable salt thereof is (R)-MDMA hydrochloride.7. The composition of any one of embodiments 1-3, wherein the (R)-MDMA or a pharmaceutically acceptable salt thereof is amorphous.8. The composition of any one of embodiments 1-7, wherein the composition comprises about 10% to about 60% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof.38336663861Attorney Docket No.: ATAI-114 / 01WO 338067-29119. The composition of any one of embodiments 1-7, wherein the composition comprises about 1% to about 40% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof.10. The composition of any one of embodiments 1-7, wherein the composition comprises about 40% to about 70% by weight of the (R)-MDMA or a pharmaceutically acceptable salt thereof.11. The composition of any one of embodiments 1-10, wherein the polymeric carrier matrix is a mucoadhesive polymer.12. The composition of any one of embodiments 1-11, wherein the polymeric carrier matrix is suitable for transmucosal application.13. The composition of embodiment 12, wherein the transmucosal application is buccal, sublingual, gingival, on the tongue, nasal, vaginal, or a rectal application.14. The composition of embodiment 13, wherein the transmucosal application is a buccal application.15. The composition of any one of embodiments 1-14, wherein the polymeric carrier matrix comprises a cellulose derivative, a polyacrylic acid, a polyacrylate, a polyethylene oxide, polyvinyl pyrrolidone, poly(vinyl pyrrolidone-co-vinyl acetate), hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, a copolymer of l-vinyl-2-pyrrolidone and vinyl acetate, propylene glycol alginate ester, tragacanth, alginate, a gum, a soluble starch, gelatin, lectin, pectin, or chitosan, or a mixture thereof.16. The composition of any one of embodiments 1-14, wherein the polymeric carrier matrix comprises carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), and a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate.17. The composition of embodiment 16, wherein the HPC of the polymeric carrier matrix comprises HPC-L, HPC-GXF, and HPC-SSL.18. The composition of any one of embodiments 1-17, wherein the composition comprises about 30% to about 70% by weight of the polymeric carrier matrix.19. The composition of any one of embodiments 1-18, wherein the composition is in the form of a film.20. The composition of embodiment 19, wherein the film is about 0.01 mm to about 2 mm thick.21. The composition of embodiment 19, wherein the film is about 0.05 mm to about 0.6 mm thick.39336663861Attorney Docket No.: ATAI-114 / 01WO 338067-291122. The composition of any one of embodiments 19-21, wherein the loss on drying (LOD) of the film is about 2-15 % w / w.23. The composition of any one of embodiments 19-22, wherein the film comprises about 1-20 mg / cm2of (R)-MDMA or a pharmaceutically acceptable salt thereof.24. The composition of any one of embodiments 19-22, a pharmaceutical strip of the film comprises about 50-80 mg per film (R)-MDMA or pharmaceutically acceptable salt thereof.25. The composition of any one of embodiments 1-24, comprising one or more of a permeation enhancer, buffering agent, saliva stimulating agent, stability enhancer, plasticizer, sweetening agent and / or a flavoring agent, coloring agent, hydrophilic adjuvant / additive or matrix solubilizing agent, antifoaming agent, or mixtures thereof.26. A mucoadhesive product comprising a backing layer and the composition of any one of embodiments 1-25.27. The mucoadhesive product of embodiment 26, wherein the backing layer is adapted to reduce or prevent MDMA or a pharmaceutically acceptable salt thereof from being transported across the backing layer while the mucoadhesive product is being administered.28. The mucoadhesive product of embodiment 26 or 27, wherein the backing layer comprises a backing polymeric carrier matrix and pigment.29. The mucoadhesive product of embodiment 28, wherein the backing polymeric carrier matrix comprises carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), and a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate.30. The mucoadhesive product of embodiment 28 and 29, wherein the pigment comprises titanium dioxide.31. The mucoadhesive product of any one of 26-30, wherein the backing layer comprises:68.42 wt % Nisso HPC-L14.31 wt % PEG3007.80 wt % CMC (ashland 7LF)5.96 wt % Plasdone S-6302.08 wt % Titanium dioxide (TiCh)1.43 wt % NaOH 50%32. A method of treating a neurological disorder in a subject in need thereof, the method comprising administering to the subject a composition comprising:40336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911about 0.5 % to about 70 % by weight of (R)-3,4-methylenedioxymethamphetamine ((R)-MDMA) or a pharmaceutically acceptable salt thereof; andabout 15% to about 80% by weight of a polymeric carrier matrix, wherein the R-MDMA or a pharmaceutically acceptable salt thereof incorporated within a polymeric carrier matrix.33. The method of embodiment 32, wherein the neurological disorder is social anxiety disorder (SAD).34. The method of embodiment 32 or 33, wherein the administration provides a (R)-MDMA Tmax of about 2 hours to about 10 hours and a (R)-MDMA Cmax of about 150 ng / mL to about 3000 ng / mL following administration.35. The method of any one of embodiments 32-24, comprising administering the composition buccally, sublingually, gingivally, on the tongue, nasally, vaginally, or rectally.36. The method of embodiment 35, comprising administering the composition buccally.37. A method of making a pharmaceutical composition, comprising:combining (R)-MDMA, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient in an aqueous solvent mixture; andremoving the aqueous solvent mixture to provide a polymeric matrix comprising (R)-MDMA or a pharmaceutically acceptable salt thereof.38. The method of embodiment 37, wherein the solvent comprises methanol and water.39. The method of embodiment 37 or 38, comprising casting the polymeric matrix by removing the aqueous solvent mixture to form a film.40. The method of any one of embodiments 37-39, wherein the composition is an oral transmucosal film.41336663861

Claims

Attorney Docket No.: ATAI-114 / 01WO 338067-2911CLAIMS1. A film composition comprising:about 20% to about 45% by weight of (R)-3,4-m ethylenedi oxymethamphetamine ((R)- MDMA) or a pharmaceutically acceptable salt thereof; anda polymeric carrier matrix,wherein the film composition has a tensile strength of about 1 MPa to about 10 MPa.

2. The film composition of claim 1, wherein the polymeric carrier matrix comprises at least two hydroxypropyl cellulose polymers having different molecular weights.

3. A film composition comprising:about 20% to about 45% by weight of (R)-3,4-m ethylenedi oxymethamphetamine ((R)- MDMA) or a pharmaceutically acceptable salt thereof; anda polymeric carrier matrix,wherein the polymeric carrier matrix comprises a polymer having a Tgbelow about 0°C.

4. The film composition of claim 3, wherein the polymeric carrier matrix further comprises a polymer having a Tgabove about 100°C.

5. A film composition comprising:about 20% to about 45% by weight of (R)-3,4-m ethylenedi oxymethamphetamine ((R)- MDMA) or a pharmaceutically acceptable salt thereof; anda polymeric carrier matrix,wherein the polymeric carrier matrix comprises a polymer having a Tgbelow about 0°C and a polymer having a Tgabove about 100°C.

6. The film composition of claim 4 or 5, wherein the polymer having a Tgabove about 100°C is selected from copovidone, povidone K30, povidone K90, and combinations thereof.

7. The film composition of any one of claims 3-5, wherein the polymer having a Tgbelow about 0°C comprises hydroxypropyl cellulose.

8. The film composition of any one of claims 3-7, wherein the polymer having a Tgbelow about 0°C comprises two hydroxypropyl cellulose polymers having different molecular weight.42336663861Attorney Docket No.: ATAI-114 / 01WO 338067-29119. The film composition of any of claims 1-8, wherein the film has a tensile strength of about 3 MPa to about 7 MPa, an elongation at break of about 30% to about 70%, as measured by ASTM D882, or a combination thereof10. The film composition of any one of claims 1-9, wherein at least 20% of the (R)- MDMA permeates in vitro through a buccal membrane within 4 hours, measured using a buccal porcine membrane assay.

11. The film composition of any one of claims 1-10, wherein the film comprises (R)- MDMA particles dispersed in the polymeric carrier matrix.

12. The film composition of any one of claims 1-10, wherein the film exhibits a loss on drying (LOD) of about 2.5% to about 6%, as determined by thermogravimetric analysis (TGA) at a temperature from 90-100 °C for a period of 10 minutes.

13. The film composition of any one of claims 1-12, wherein the (R)-MDMA is uniformly distributed throughout the film, determined according to USP <905> “Uniformity of Dosage Unites Content Uniformity CU ”14. The film composition of any one of claims 1-13, wherein the film has a folding endurance of at least 10 folds without breaking.

15. The film composition of any of claims 1-14, further comprising a buffering agent.

16. The film composition of any of claims 1-15, further comprising a buffering agent in an amount sufficient to provide, upon hydration of the film, a film surface pH of about 7.5 to about 8.5.

17. The film composition of claim 15 or 16, wherein the buffering agent comprises sodium carbonate, sodium bicarbonate, or a combination thereof.

18. The film composition of any one of claims 1-17, wherein the film has a folding endurance of at least 10 folds without breaking.

19. The film composition of any one of claims 1-18, wherein the film further comprises a permeation enhancer.

20. The film composition of any one of claims 1-19, wherein the film further comprises a permeation enhancer in an amount from about 1% to about 4% by weight.

21. The film composition of claim 18, wherein the permeation enhancer comprises propylene glycol, glycerol, polyethylene glycol, or a combination thereof.

22. The film composition of any one of claims 3-21, wherein the at least two hydroxypropyl cellulose polymers having different molecular weight are selected from hydroxypropyl cellulose SSL, hydroxypropyl cellulose LF, hydroxypropyl cellulose MF, hydroxypropyl cellulose GXF, and combinations thereof43336663861Attorney Docket No.: ATAI-114 / 01WO 338067-291123. The film composition of any one of claims 1-22, wherein the film further comprises a coloring agent selected from titanium dioxide and zinc oxide24. The film composition of any one of claims 1-23, wherein the (R)-MDMA or pharmaceutically acceptable salt thereof is (R)-MDMA hydrochloride.

25. The film composition of any one of claims 1-24, wherein the film further comprises a flavoring agent, sweetening agent, a bitter masking agent, or a combination thereof.

26. The film composition of any one of claims 1-25, comprising:propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF; andhydroxypropyl cellulose MF.

27. The film composition of any one of claims 1-25, comprising:propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF; andhydroxypropyl cellulose SSL.

28. The film composition of any one of claims 1-25, comprising:propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF; andcopovidone.

29. The film composition of any one of claims 1-25, comprising:propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF;copovidone; andhydroxypropyl cellulose SSL.

30. The film composition of any one of claims 1-25, comprising:glycerol44336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911propylene glycol;hydroxypropyl cellulose LF; andhydroxypropyl cellulose MF.

31. The film composition of any one of claims 1-25, comprising:glycerolpropylene glycol;hydroxypropyl cellulose LF; andhydroxypropyl cellulose SSL.

32. The film composition of any one of claims 1-25, comprising:glycerolpropylene glycol;hydroxypropyl cellulose LF; andcopovidone.

33. The film composition of any one of claims 1-25, comprising:glycerolpropylene glycol;hydroxypropyl cellulose LF;copovidone; andhydroxypropyl cellulose SSL.

34. The film composition of any one of claims 1-25, comprising:glycerol;polyethylene glycol 300;hydroxypropyl cellulose LF; andhydroxypropyl cellulose MF.

35. The film composition of any one of claims 1-25, comprising:glycerol;polyethylene glycol 300;45336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911hydroxypropyl cellulose LF; andhydroxypropyl cellulose SSL.

36. The film composition of any one of claims 1-25, comprising:glycerol;polyethylene glycol 300;hydroxypropyl cellulose LF; andcopovidone.

37. The film composition of any one of claims 1-25, comprising:glycerol;polyethylene glycol 300;hydroxypropyl cellulose LF;copovidone; andhydroxypropyl cellulose SSL.

38. The film composition of any one of claims 1-25, comprising:glycerol;propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF; andhydroxypropyl cellulose MF.

39. The film composition of any one of claims 1-25, comprising:glycerol;propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF; andhydroxypropyl cellulose SSL.

40. The film composition of any one of claims 1-25, comprising:glycerol;46336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF; andcopovidone.

41. The film composition of any one of claims 1-25, comprising:glycerol;propylene glycol;polyethylene glycol 300;hydroxypropyl cellulose LF;copovidone; andhydroxypropyl cellulose SSL.

42. The film composition of any of claims 26-41, further comprising hydroxypropyl cellulose GXF.

43. The film composition of any one of claims 1-25, comprising:propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

44. The film composition of any one of claims 1-25, comprising:propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

45. The film composition of any one of claims 1-25, comprising:propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and47336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911copovidone in an amount of about 2% to about 10% by weight.

46. The film composition of any one of claims 1-25, comprising:propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; copovidone in an amount of about 2% to about 10% by weight; and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

47. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

48. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

49. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and copovidone in an amount of about 2% to about 10% by weight.

50. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; copovidone in an amount of about 2% to about 10% by weight; and48336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

51. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

52. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

53. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and copovidone in an amount of about 2% to about 10% by weight.

54. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; copovidone in an amount of about 2% to about 10% by weight; and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

55. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and49336663861Attorney Docket No.: ATAI-114 / 01WO 338067-2911hydroxypropyl cellulose MF in an amount of about 2% to about 10% by weight.

56. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

57. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; and copovidone in an amount of about 2% to about 10% by weight.

58. The film composition of any one of claims 1-25, comprising:glycerol in an amount of about 0.1% to about 3% by weight;propylene glycol in an amount of about 0.1% to about 3% by weight; polyethylene glycol 300 in an amount of about 0.1% to about 3% by weight; hydroxypropyl cellulose LF in an amount of about 20% to about 60% by weight; copovidone in an amount of about 2% to about 10% by weight; and hydroxypropyl cellulose SSL in an amount of about 2% to about 10% by weight.

59. The film composition of any of claims 43-58, further comprising hydroxypropyl cellulose GXF in amount of about 2% to about 10% by weight.

60. The film composition of any of claims 43-58, wherein the combined propylene glycol, polyethylene glycol, and / or glycerol are present in an amount that does not exceed 4% by weight.

61. The film composition of any of claims 1-60, comprising (R)-MDMA or a pharmaceutically acceptable salt thereof in an amount from 20% to 40% by weight, 25% to 40% by weight, 30% to 40% by weight, 35% to 40% by weight, 30% to 45% by weight, 35% to 45% by weight, or 40% to 45% by weight.50336663861Attorney Docket No.: ATAI-114 / 01WO 338067-291162. A method of making a film composition comprising (R)-MDMA or a pharmaceutically acceptable salt thereof, the method comprising:(a) providing a solvent system comprising a low-polarity solvent and a polar solvent, wherein the low-polarity solvent fraction exceeds the polar solvent fraction by weight; (b) dispersing (R)-MDMA or pharmaceutically acceptable salt thereof in the solvent system to form a mixture; and(c) casting the mixture onto a substrate and removing the solvent to provide the film composition.

63. The method of claim 62, wherein the solvent system further comprises at least one polymer.

64. The method of claim 62 or 63, wherein the solvent system further comprises at least one permeation enhancer.

65. The method of any of claims 62-64, wherein the solvent system further comprises a buffering agent.

66. The method of any of claims 62-65, further comprising de-aerating the mixture of step (b) prior to casting the mixture on the substrate.

67. The method of any of claims 62-66, wherein the low-polarity solvent comprises ethyl acetate or methyl ethyl ketone.

68. The method of any of claims 62-67, wherein the polar solvent comprises an alcohol.

69. The method of any of claim 62-68, wherein the polar solvent comprises isopropanol.

70. The method of any of claims 62-69, wherein the ratio of low-polarity solvent to polar solvent is about 80:20 by weight.

71. The method of any of claims 64-69, wherein the permeation enhancer comprises propylene glycol, polyethylene glycol, glycerol, or a combination thereof.

72. The method of any of claims 64-70, wherein the buffering agent is selected from sodium carbonate, sodium bicarbonate, and combinations thereof.

73. The method of any of claims 63-71, wherein the at least one polymer comprises a polymer having a Tgbelow about 0°C.

74. The method of any of claims 63-72, wherein the at least one polymer further comprises a polymer having a Tgabove about 100°C.

75. The method of claim 73, wherein the polymer having a Tgbelow about 0°C comprises two hydroxypropyl cellulose polymers having different molecular weight.51336663861Attorney Docket No.: ATAI-114 / 01WO 338067-291176. The method of claim 75, wherein the at least two hydroxypropyl cellulose polymers having different molecular weight are selected from hydroxypropyl cellulose SSL, hydroxypropyl cellulose LF, hydroxypropyl cellulose MF, hydroxypropyl cellulose GXF, and combinations thereof.

77. The method of claim 74, wherein the polymer having a Tgabove about 100°C is selected from copovidone, povidone K30, povidone K90, and combinations thereof.

78. The method of any of claims 62-77, further comprising adding to the solvent system a coloring agent, a flavorant, a sweetener, a bitter masking agent, or a combination thereof.

79. The method of claim 78, wherein the coloring agent comprises titanium dioxide, zinc oxide, or a combination thereof.

80. The method of any of claims 62-79, wherein the (R)-MDMA or pharmaceutically acceptable salt thereof is (R)-MDMA hydrochloride.

81. A film composition prepared by the method of any of claims 62-80.

82. A method of treating an anxiety disorder in a subject in need thereof, comprising administering to the subject the film composition of any of claims 1-61 or 81.

83. The method of claim 82, wherein the anxiety disorder is social anxiety disorder.

84. The method of claim 83, wherein the anxiety disorder is generalized anxiety disorder.

85. The method of any one of claims 82-84, wherein the subject has one or more conditions comorbid with the anxiety disorder.

86. The method of claim 85, wherein the one or more conditions comorbid with an anxiety disorder is a mood disorder, a depressive disorder, an anxious distress, a rejection sensitivity, a mixed anxiety and depressive disorder (MADD), a major depressive disorder, or a treatment resistant depression, a bipolar disorder, schizophrenia, an eating disorder, an attention deficit / hyperactivity disorder, epilepsy, a cardiovascular disease, a substance abuse disorder, migraine, a headache disorder, an irritable bowel syndrome, a dementia, post-traumatic stress disorder (PTSD), Alzheimer’s disease, Parkinson’s disease, or any combination thereof.

87. The method of claim 86, wherein the eating disorder comprises anorexia nervosa, bulimia nervosa, or binge eating.

88. The method of claim 86, wherein the substance abuse disorder comprises alcohol abuse, caffeine abuse, cannabis abuse, hallucinogen abuse, inhalant abuse, opioid abuse, sedative abuse, hypnotic abuse, anxiolytic abuse, stimulant abuse, or tobacco abuse.52336663861Attorney Docket No.: ATAI-114 / 01WO 338067-291189. The method of claim 88, wherein the hallucinogen is selected from phencyclidine or similarly acting arylcyclohexylamines, and lysergic acid diethylamide (LSD).

90. The method of claim 88, wherein the stimulant is selected from amphetamine-type substances and cocaine.

91. The method of any of claims 82-90, wherein administering the film composition comprises applying the film composition to a surface inside the mouth, rectum, nasal cavity, or vagina of the subject.

92. The method of any of claims 82-91, wherein administering the film composition comprises applying the film composition buccally, sublingually, gingivally, or on the tongue.

93. The method of any of claims 82-92, wherein administering the film composition comprises applying the film composition buccally.53336663861